Evidence map›Paper›PMID 38124159›Full record

ArticleBMC chemistry2023

Synthesis of 3-formyl-eudistomin U with anti-proliferation, anti-migration and apoptosis-promoting activities on melanoma cells.

Jixiang Gao, Jinyi Liu, Tao Yu, Chenggong Xu, Hao Sun, Chunbo Lu, Wenjia Dan, Jiangkun Dai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jixiang Gao *School of Life Science and Technology, Weifang Medical University, Weifang, Shandong Province, 261053, China.
Jinyi Liu *School of Life Science and Technology, Weifang Medical University, Weifang, Shandong Province, 261053, China.
Tao Yu *School of Life Science and Technology, Weifang Medical University, Weifang, Shandong Province, 261053, China.
Chenggong XuSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong Province, 261053, China.
Hao SunSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong Province, 261053, China.
Chunbo LuSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong Province, 261053, China.
Wenjia DanSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong Province, 261053, China. dwj586@163.com.
Jiangkun DaiSchool of Life Science and Technology, Weifang Medical University, Weifang, Shandong Province, 261053, China. daijkun@hotmail.com.
Weifang Medical University · CN

Funding

National Natural Science Foundation of China 82003595 and 82204274Natural Science Foundation of Shandong Province 2023HWYQ-096, ZR2022QH021 and ZR2020QH346
6 · The paper itself

Abstract

The discovery of new lead skeleton against melanoma are urgently needed due to its highly malignant and mortality. Herein, a new molecular entity (EU-5) derived from eudistomin U was synthesized with total yield of 46%, which displayed potent activity against malignant melanoma A375 cells (IC

Indexed as

Anti-melanomaDNAEudistomin USynthesisTranscriptome

Identifiers

PMID38124159
PMCPMC10734049
OpenAlexW4389991956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.